106 related articles for article (PubMed ID: 12943693)
21. Expression of estrogen-responsive finger protein (Efp) is associated with advanced disease in human epithelial ovarian cancer.
Sakuma M; Akahira J; Suzuki T; Inoue S; Ito K; Moriya T; Sasano H; Okamura K; Yaegashi N
Gynecol Oncol; 2005 Dec; 99(3):664-70. PubMed ID: 16140366
[TBL] [Abstract][Full Text] [Related]
22. Efp promotes growth of triple-negative breast cancer cells.
Sato W; Ikeda K; Gotoh N; Inoue S; Horie K
Biochem Biophys Res Commun; 2022 Oct; 624():81-88. PubMed ID: 35940131
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers.
Horie-Inoue K; Inoue S
Semin Cancer Biol; 2006 Jun; 16(3):235-9. PubMed ID: 16682214
[TBL] [Abstract][Full Text] [Related]
24. Combined Use of Immunoreactivities of RIG-I with Efp/TRIM25 for Predicting Prognosis of Patients With Estrogen Receptor-positive Breast Cancer.
Sato J; Azuma K; Kinowaki K; Ikeda K; Ogura T; Takazawa Y; Kawabata H; Kitagawa M; Inoue S
Clin Breast Cancer; 2021 Oct; 21(5):399-407.e2. PubMed ID: 33386231
[TBL] [Abstract][Full Text] [Related]
25. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Chu I; Blackwell K; Chen S; Slingerland J
Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
[TBL] [Abstract][Full Text] [Related]
26. Ligand-dependent transcription of estrogen receptor alpha is mediated by the ubiquitin ligase EFP.
Nakajima A; Maruyama S; Bohgaki M; Miyajima N; Tsukiyama T; Sakuragi N; Hatakeyama S
Biochem Biophys Res Commun; 2007 May; 357(1):245-51. PubMed ID: 17418098
[TBL] [Abstract][Full Text] [Related]
27. Uterine preparation for implantation in the mouse is associated with coordinate expression of estrogen-responsive finger protein and estrogen receptor.
Das N; Wang J; Dey SK
Mol Reprod Dev; 1997 Apr; 46(4):499-506. PubMed ID: 9094097
[TBL] [Abstract][Full Text] [Related]
28. Negative regulation of ISG15 E3 ligase EFP through its autoISGylation.
Zou W; Wang J; Zhang DE
Biochem Biophys Res Commun; 2007 Mar; 354(1):321-7. PubMed ID: 17222803
[TBL] [Abstract][Full Text] [Related]
29. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
Osborne CK; Hobbs K; Clark GM
Cancer Res; 1985 Feb; 45(2):584-90. PubMed ID: 3967234
[TBL] [Abstract][Full Text] [Related]
30. Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines.
Gomez BP; Riggins RB; Shajahan AN; Klimach U; Wang A; Crawford AC; Zhu Y; Zwart A; Wang M; Clarke R
FASEB J; 2007 Dec; 21(14):4013-27. PubMed ID: 17660348
[TBL] [Abstract][Full Text] [Related]
31. The prediction of hormonal dependency of mammary cancer.
Block GE; Jensen EV; Polley TZ
Ann Surg; 1975 Sep; 182(3):342-52. PubMed ID: 169754
[TBL] [Abstract][Full Text] [Related]
32. Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer.
Ojo D; Lin X; Wu Y; Cockburn J; Bane A; Tang D
Cancer Lett; 2018 Jul; 426():4-13. PubMed ID: 29626519
[TBL] [Abstract][Full Text] [Related]
33. ERE-independent ERalpha target genes differentially expressed in human breast tumors.
Glidewell-Kenney C; Weiss J; Lee EJ; Pillai S; Ishikawa T; Ariazi EA; Jameson JL
Mol Cell Endocrinol; 2005 Dec; 245(1-2):53-9. PubMed ID: 16298037
[TBL] [Abstract][Full Text] [Related]
34. Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro.
Reddel RR; Sutherland RL
Cancer Res; 1987 Oct; 47(20):5323-9. PubMed ID: 3652038
[TBL] [Abstract][Full Text] [Related]
35. [Estrogens, cathepsin D and metastasis in cancers of the breast and ovary: invasion or proliferation?].
Rochefort H
C R Seances Soc Biol Fil; 1998; 192(2):241-51. PubMed ID: 9841098
[TBL] [Abstract][Full Text] [Related]
36. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
Nakata T; Takashima S; Shiotsu Y; Murakata C; Ishida H; Akinaga S; Li PK; Sasano H; Suzuki T; Saeki T
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):455-60. PubMed ID: 14623544
[TBL] [Abstract][Full Text] [Related]
37. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
38. Systemic distribution of estrogen-responsive finger protein (Efp) in human tissues.
Shimada N; Suzuki T; Inoue S; Kato K; Imatani A; Sekine H; Ohara S; Shimosegawa T; Sasano H
Mol Cell Endocrinol; 2004 Apr; 218(1-2):147-53. PubMed ID: 15130519
[TBL] [Abstract][Full Text] [Related]
39. Multiple regulatory elements and binding proteins of the 5'-flanking region of the human estrogen-responsive finger protein (efp) gene.
Ikeda K; Inoue S; Orimo A; Sano M; Watanabe T; Tsutsumi K; Muramatsu M
Biochem Biophys Res Commun; 1997 Jul; 236(3):765-71. PubMed ID: 9245730
[TBL] [Abstract][Full Text] [Related]
40. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
